Seysara (Sarecycline HCl) Patent Expiration, LOE Window & CMS Spending

Seysara (Sarecycline HCl) by Almirall: FDA Orange Book core substance LOE 2033-02-09, 0 AB generics, $786K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAlmirall
FDA Application & PathwayN209521 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2033-02-09
Last Listed Patent or Exclusivity Date2033-02-09
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$786K
2024 Medicare Part D Spend$786K
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel